AGP Picks
View all

MarCom Europe
Provided by AGP

MarCom Europe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on MarCom Europe.

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

Press releases published on May 21, 2026

FRAGMENTS OF BEING Premieres at Cannes Marché du Film: Exploring Being Through Fragmented Consciousness
May 21, 2026

FRAGMENTS OF BEING Premieres at Cannes Marché du Film: Exploring Being Through Fragmented Consciousness

Indeterminate EIN Presswire
Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma
May 21, 2026

Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma

Indeterminate GlobeNewswire
nVent to Participate in Upcoming Investor Conference
May 21, 2026

nVent to Participate in Upcoming Investor Conference

Indeterminate GlobeNewswire
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
May 21, 2026

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Indeterminate GlobeNewswire
Peace Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering
May 21, 2026

Peace Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering

Indeterminate GlobeNewswire
Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
May 21, 2026

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Indeterminate GlobeNewswire
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
May 21, 2026

Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering

Indeterminate GlobeNewswire
Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026
May 21, 2026

Autolus Therapeutics to Present Clinical Data Update at the American Society of Clinical Oncology Annual Meeting 2026

Indeterminate GlobeNewswire
Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology
May 21, 2026

Eikon Therapeutics Announces Availability of Six Abstracts for Presentation at the 2026 Annual Meeting of the American Society of Clinical Oncology

Indeterminate GlobeNewswire
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
May 21, 2026

Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin

Indeterminate GlobeNewswire
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
May 21, 2026

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

Indeterminate GlobeNewswire
AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit
May 21, 2026

AerSale Announces Participation at the 2026 Jefferies Aftermarket MRO Virtual Summit

Indeterminate GlobeNewswire
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
May 21, 2026

Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire
NVIDIA Announces Upcoming Events for Financial Community
May 21, 2026

NVIDIA Announces Upcoming Events for Financial Community

Indeterminate GlobeNewswire
Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting
May 21, 2026

Compass Therapeutics to Present Promising Phase 1 Clinical Data for CTX-8371 in Patients with Advanced Malignancies Treated in the Post-Checkpoint Inhibitor Setting at the 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire
Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC
May 21, 2026

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

Indeterminate GlobeNewswire
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
May 21, 2026

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy

Indeterminate GlobeNewswire
BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting
May 21, 2026

BlossomHill Therapeutics to Present Preliminary Results From Phase 1 Dose Escalation/Backfill Cohorts in Phase 1/2 SOLARA Trial of OMNI-EGFR Inhibitor, BH-30643, in Advanced EGFR-mutant NSCLC at the 2026 ASCO Annual Meeting

Indeterminate GlobeNewswire
Zodiac Partners II, LLC Provides an Update to its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash
May 21, 2026

Zodiac Partners II, LLC Provides an Update to its Previously Announced $46 million Tender Offer to Acquire Destination XL Group, Inc. for $0.82 Per Share in Cash

Indeterminate GlobeNewswire
Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline
May 21, 2026

Asher Biotherapeutics Announces Two Presentations at the ASCO 2026 Annual Meeting Highlighting Clinical Progress Across Its CD8-Targeted Cytokine Pipeline

Indeterminate GlobeNewswire
Show More

Share this page:

Sign up for:

MarCom Europe

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.